MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
12.77
+1.02 (8.68%)
At close: Nov 12, 2025, 4:00 PM EST
12.78
+0.01 (0.08%)
After-hours: Nov 12, 2025, 7:01 PM EST
MLTX Employees
MoonLake Immunotherapeutics had 100 employees as of December 31, 2024. The number of employees increased by 50 or 100.00% compared to the previous year.
Employees
100
Change (1Y)
50
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$2,104,955
Market Cap
911.44M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100 | 50 | 100.00% |
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MLTX News
- 2 days ago - MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Newsfile Corp
- 2 days ago - MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline - GlobeNewsWire
- 2 days ago - MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline - Newsfile Corp
- 7 days ago - MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering - GlobeNewsWire
- 7 days ago - MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab - GlobeNewsWire
- 11 days ago - MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses - GlobeNewsWire
- 15 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - PRNewsWire
- 4 weeks ago - MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman - PRNewsWire